MorphoSys is developing a proprietary portfolio of innovative therapeutic antibodies to treat cancer and inflammatory diseases. Our intent is to develop these compounds to clinical proof of concept before partnering.
The most advanced compound MOR103, an anti-GM-CSF antibody to treat inflammatory conditions, is currently being evaluated in a phase 1b/2a clinical trial in patients with active rheumatoid arthritis. Two further programs, MOR208 and MOR202, are in clinical development for oncology, more specifically for hematological malignancies.
